Gulfo Might Reevaluate Negotiated User Fees If Selected US FDA Commish
Joseph Gulfo, a former medtech industry CEO and vocal FDA critic, is the latest candidate apparently being considered for FDA commissioner. In an interview with Medtech Insight, he outlines his worldview and interest in pushing aggressively against increasing the FDA "body of law."
You may also be interested in...
The House Energy and Commerce Committee Democrat says few in-depth member talks about user-fee bills have taken place because of a focus on Affordable Care Act repeal and replacement.
O'Neill and Srinivasan head to Trump Tower, but Gottlieb has not been eliminated.
More specific details have emerged about the agreement "in principle" announced last week by FDA and industry negotiators on the next round of the medical device user-fee program, which will extend from fiscal years 2018 through 2022.